Current status of molecular-targeted drugs for endometrial cancer (Review)

Area of Science:

• Gynecology
• Oncology
• Molecular Biology

Background:

• Endometrial cancer is a prevalent gynecological malignancy with increasing incidence globally.
• Understanding the genetic and molecular mechanisms underlying endometrial cancer is crucial for developing effective treatments.
• Current chemotherapy often leads to severe side effects and lacks established regimens for rare histological types.

Purpose of the Study:

• To review the advancements in understanding endometrial cancer's molecular basis.
• To explore the potential of molecular-targeted drugs in treating endometrial cancer.
• To identify challenges and future directions for improving treatment efficacy.

Main Methods:

• Review of recent studies on endometrial cancer genetics and molecular pathways.
• Analysis of molecular-targeted drug development and application.
• Examination of treatment response rates and associated challenges.

Main Results:

• Genetic abnormalities and molecular signaling pathways are increasingly elucidated in endometrial cancer.
• Molecular-targeted drugs offer potential new treatment avenues, but single-agent efficacy is limited.
• Distinct genetic profiles exist among different histological types of endometrial cancer.

Conclusions:

• Targeting molecular and genetic mechanisms holds promise for endometrial cancer therapy.
• Low response rates with single-agent molecular-targeted drugs highlight the need for further research.
• Combination therapies and identification of sensitivity factors are essential for overcoming current treatment limitations.